GeneDx shares plunge 49% after Q1 earnings miss and lowered 2026 guidance sparks legal probe

GeneDx Holdings saw its stock drop 49% after reporting a massive Q1 2026 loss and cutting full-year revenue guidance by 12%, driven by a shift to lower-reimbursed genome tests. This wiped out over $900 million in market value and prompted law firm Hagens Berman to investigate potential securities law violations for possibly misleading investors about growth prospects. The firm encourages affected investors to come forward as the case develops.